The United Kingdom and the United States have secured a major bilateral deal that will ensure no levies on British drug exports going into the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to increase spending on drugs through the National Health Service (NHS). This commitment ensures that duties on these key exports will stay at zero for a timeframe of 36 months.
This deal is in response to previous warnings to significantly raise tariffs on branded drug products, with figures discussed reaching 100%.
"This arrangement between the Britain bolsters the global environment for cutting-edge drugs and establishes long-overdue balance to transatlantic medicine commerce," an announcement noted.
Economic Importance
Drugs constitute one of the the United Kingdom's largest goods shipped to the America, which is easily the largest buyer for large UK drugmakers.
Statistics indicate that in the 12 months prior to September, the UK sold drugs totaling billions to the US. This figure made up 17.4% of all goods exports in that timeframe.
"This deal safeguards jobs, boosts capital expenditure and paves the way for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The agreement entails several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall NHS spending on medicines from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must refund to the NHS to control costs will be limited at fifteen percent. Previously, refunds were more than 20%.
Industry Background
The pact takes place against a ongoing row between the drug companies and the ministers over spending levels and NHS adoption.
This friction were exacerbated by claims that US consumers were charged a premium for the same drugs than patients in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while substantial expansions have been pledged toward American operations.
One official stated that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the past decade.